Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Search by expertise, name or affiliation
Comparison of potential markers of farnesyltransferase inhibition
Alex A. Adjei
,
Jenny N. Davis
, Charles Erlichman
, Phyllis A. Svingen
, Scott H. Kaufmann
Pediatric Epidemiology & Clinical Research
Research output
:
Contribution to journal
›
Article
›
peer-review
120
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Comparison of potential markers of farnesyltransferase inhibition'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Farnesyltransferase
100%
Farnesyltransferase Inhibitor
100%
Polypeptide
50%
Lamin
50%
P21Cip1
50%
Neoplastic Cells
50%
Prelamin A
50%
Histology
25%
Phase II Clinical Trial
25%
Clinical Samples
25%
Signaling Pathway
25%
Immunohistochemistry
25%
Enzymatic Activity
25%
Nonapeptides
25%
Cellular Effects
25%
Drug-induced
25%
Clinical Setting
25%
Ras Proteins
25%
Antiserum
25%
Chaperone Proteins
25%
MCF-7
25%
Immunoblotting
25%
Intranuclear
25%
A549
25%
BxPC-3
25%
Cycling Cells
25%
HCT116
25%
SCH66336
25%
Mobility Shift
25%
Peptidomimetic Inhibitors
25%
Precursor Peptide
25%
Intermediate Filament Proteins
25%
Activity Evaluation
25%
Medicine and Dentistry
Farnesyltransferase Inhibitor
100%
Polypeptide
50%
P21
50%
Lamin A
50%
Cell Line
50%
Clinical Trial
25%
Precursor
25%
Cell Signaling Pathway
25%
Immunohistochemistry
25%
Ras Protein
25%
Enzyme Activity
25%
Chaperone
25%
MCF-7
25%
Lonafarnib
25%
Immunoblotting
25%
Antiserum
25%
Intermediate Filament Protein
25%
Peptidomimetics
25%
Neuroscience
Farnesyltransferase Inhibitor
100%
Cell Line
50%
Polypeptide
50%
Lamin A
50%
Enzyme Activity
25%
Chaperone
25%
Ras Protein
25%
Intermediate Filament Protein
25%
Immunohistochemistry
25%
Antiserum
25%
Immunoblotting
25%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Farnesyltransferase Inhibitor
100%
Polypeptide
50%
Lamin A
50%
Clinical Trial
25%
Western Blot
25%
Chaperone
25%
Ras Protein
25%
Antiserum
25%
Lonafarnib
25%
Intermediate Filament Protein
25%
Peptidomimetics
25%